Disitamab Vedotin for Injection (generic name: Disitamab Vedotin) is an antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors (e.g., gastric cancer, urothelial carcinoma, etc.). As a prescription drug, it must be used under the guidance of a physician. Its price is affected by factors such as specification, region and medical institution, with the unit price usually ranging from US$2,170 to US$2,893. The actual price shall prevail based on the purchasing channel.
Notes on Price and Usage
1. Price Influencing Factors
Specification difference
Common specifications are 40mg/vial and 60mg/vial, with different prices for different specifications.
Purchasing channel
Prices may vary slightly among public hospitals, designated pharmacies or authorized platforms. It is recommended to obtain the drug through formal medical institutions.
Medical insurance policy
At present, some indications of this drug are covered by medical insurance (e.g., third-line treatment for gastric cancer), but eligibility for medical insurance reimbursement must be met. The specific reimbursement ratio shall be consulted with the local medical insurance department.
2. Medication Precautions
Strictly follow medical advice
The dosage must be calculated according to the patient's condition, body surface area, etc., and a professional doctor shall formulate the treatment plan. Do not adjust the dosage or stop the drug without authorization.
Side effect management
Common adverse reactions include leukopenia, peripheral neuropathy, etc. Regular monitoring of blood routine and liver & kidney function is required during medication.
Contraindications and precautions for use
It is contraindicated in patients with hypersensitivity to the drug ingredients. Careful risk assessment shall be conducted for pregnant women, lactating women and patients with severe liver and kidney insufficiency.
3. Access and Assistance Information
Purchase from hospitals or designated pharmacies
A prescription is required for purchase. It is recommended to choose the oncology department of tertiary hospitals or specialized pharmacies.
Patient assistance programs
Some enterprises or charitable institutions provide medication subsidies or installment payment plans. The specific application process can be consulted with the attending physician or pharmacist.
Medical Guidance
If you need to use this drug, it is recommended to visit the oncology department of a specialized cancer hospital or a general hospital, where a doctor will evaluate the indications and issue a prescription.
Regular follow-up visits are required during treatment to monitor efficacy and adverse reactions.
Do not purchase the drug through informal channels to avoid the risk of counterfeit medicines.
